Pathology of gastric intestinal metaplasia: Clinical implications

American Journal of Gastroenterology

Volumn 105, Issue 3, 2010, Pages 493-498

  Correa, Pelayo ^a   Piazuelo, M Blanca ^a   Wilson, Keith T ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIA; DISEASE CLASSIFICATION; HISTOPATHOLOGY; HUMAN; INTESTINE METAPLASIA; NOMENCLATURE; PRIORITY JOURNAL; REVIEW;

ADENOCARCINOMA; ALGORITHMS; BIOPSY; DISEASE PROGRESSION; ENDOSCOPY, GASTROINTESTINAL; HUMANS; METAPLASIA; PEPSINOGEN A; PRECANCEROUS CONDITIONS; RISK FACTORS; STAINING AND LABELING; STOMACH; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77749251829     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.728     Document Type: Review

References (60)

1. Correa P. Human gastric carcinogenesis:a multistep and multifactorial process. First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735-6740
2. Fennerty MB. Gastric intestinal metaplasia on routine endoscopic biopsy. Gastroenterology 2003;125:586-590
3. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 2002;11:235-256
4. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-2053
5. Goldblum JR, Richter JE, Vaezi M, et al. Helicobacter pylori infection, not gastroesophageal reflux, is the major cause of inflammation and intestinal metaplasia of gastric cardiac mucosa. Am J Gastroenterol 2002;97:302-311
6. Hansen S, Vollset SE, Derakhshan MH, et al. Two distinct aetiologies of cardia cancer;evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut 2007;56:918-925
7. Srivastava A, Odze RD, Lauwers GY, et al. Morphologic features are useful in distinguishing Barrett esophagus from carditis with intestinal metaplasia. Am J Surg Pathol 2007;31:1733-1741
8. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
9. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 61. Schistosomes, Liver Flukes and Helicobacter pylori. International Agency for Research on Cancer, World Health Organization:Lyon, France, 1994.
10. Correa P, Haenszel W, Cuello C, et al. A model for gastric cancer epidemiology. Lancet 1975;2:58-60.
11. Filipe MI, Munoz N, Matko I, et al. Intestinal metaplasia types and the risk of gastric cancer:a cohort study in Slovenia. Int J Cancer 1994;57:324-329
12. Espey DK, Wu XC, Swan J, et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer 2007;110:2119-2152
13. Wu X, Chen VW, Andrews PA, et al. Incidence of esophageal and gastric cancers among Hispanics, non-Hispanic whites and non-Hispanic blacks in the United States:subsite and histology differences. Cancer Causes Control 2007;18:585-593
14. Fennerty MB, Emerson JC, Sampliner RE, et al. Gastric intestinal metaplasia in ethnic groups in the southwestern United States. Cancer Epidemiol Biomarkers Prev 1992;1:293-296
15. Camorlinga-Ponce M, Flores-Luna L, Lazcano-Ponce E, et al. Age and severity of mucosal lesions influence the performance of serologic markers in Helicobacter pylori-associated gastroduodenal pathologies. Cancer Epidemiol Biomarkers Prev 2008;17:2498-2504
16. de Vries AC, Haringsma J, de Vries RA, et al. The use of clinical, histologic, and serologic parameters to predict the intragastric extent of intestinal metaplasia:a recommendation for routine practice. Gastrointest Endosc 2009;70:18-25.
17. Fontham E, Zavala D, Correa P, et al. Diet and chronic atrophic gastritis:a case-control study. J Natl Cancer Inst 1986;76:621-627
18. Kneller RW, You WC, Chang YS, et al. Cigarette smoking and other risk factors for progression of precancerous stomach lesions. J Natl Cancer Inst 1992;84:1261-1266
19. Leung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia:results of a randomised trial on Helicobacter pylori eradication. Gut 2004;53:1244-1249
20. Leung WK, Sung JJ. Review article:Intestinal metaplasia and gastric carcinogenesis. Aliment Pharmacol Ther 2002;16:1209-1216
21. You WC, Chang YS. Epidemiology of precancerous gastric lesions. J Gastroenterol Hepatol 1993;8:375-382
22. Correa P, Cuello C, Duque E. Carcinoma and intestinal metaplasia of the stomach in Colombian migrants. J Natl Cancer Inst 1970;44:297
23. Con SA, Con-Wong R, Con-Chin GR, et al. Serum pepsinogen levels, Helicobacter pylori CagA status, and cytokine gene polymorphisms associated with gastric premalignant lesions in Costa Rica. Cancer Epidemiol Biomarkers Prev 2007;16:2631-2636
24. Parsonnet J, Friedman GD, Orentreich N, et al. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997;40:297-301. (Pubitemid 27145639)
25. Peek RM Jr., Crabtree JE. Helicobacter infection and gastric neoplasia. J Pathol 2006;208:233-248
26. Zabaleta J, Camargo MC, Piazuelo MB, et al. Association of interleukin-1beta gene polymorphisms with precancerous gastric lesions in African Americans and Caucasians. Am J Gastroenterol 2006;101:163-171
27. Heilmann KL, Hopker WW. Loss of differentiation in intestinal metaplasia in cancerous stomachs. A comparative morphologic study. Pathol Res Pract 1979;164:249-258
28. Jass JR, Filipe MI. The mucin profiles of normal gastric mucosa, intestinal metaplasia and its variants and gastric carcinoma. Histochem J 1981;13:931-939
29. Matsukura N, Suzuki K, Kawachi T, et al. Distribution of marker enzymes and mucin in intestinal metaplasia in human stomach and relation to complete and incomplete types of intestinal metaplasia to minute gastric carcinomas. J Natl Cancer Inst 1980;65:231-240
30. Teglbjaerg PS, Nielsen HO. "Small intestinal type" and "colonic type" intestinal metaplasia of the human stomach, and their relationship to the histogenetic types of gastric adenocarcinoma. Acta Pathol Microbiol Scand A 1978;86A:351-355
31. Gutierrez-Gonzalez L, Wright NA. Biology of intestinal metaplasia in 2008:more than a simple phenotypic alteration. Dig Liver Dis 2008;40:510-522
32. Reis CA, David L, Correa P, et al. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. Cancer Res 1999;59:1003-1007
33. Silva E, Teixeira A, David L, et al. Mucins as key molecules for the classification of intestinal metaplasia of the stomach. Virchows Arch 2002;440:311-317
34. Piazuelo MB, Haque S, Delgado A, et al. Phenotypic differences between esophageal and gastric intestinal metaplasia. Mod Pathol 2004;17:62-74.
35. Cassaro M, Rugge M, Gutierrez O, et al. Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol 2000;95:1431-1438
36. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-1181
37. Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline:the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006;63:570-580
38. Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis:a tutorial. Dig Liver Dis 2008;40:650-658
39. Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut 1991;32:1110-1113
40. Silva S, Filipe MI. Intestinal metaplasia and its variants in the gastric mucosa of Portuguese subjects:a comparative analysis of biopsy and gastrectomy material. Hum Pathol 1986;17:988-995
41. SamloffIM, Varis K, Ihamaki T, et al. Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology 1982;83:204-209
42. di Mario F, Cavallaro LG. Non-invasive tests in gastric diseases. Dig Liver Dis 2008;40:523-530
43. Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis 2007;8:8-14.
44. Watanabe Y, Kurata JH, Mizuno S, et al. Helicobacter pylori infection and gastric cancer. A nested case-control study in a rural area of Japan. Dig Dis Sci 1997;42:1383-1387 (Pubitemid 27339350)
45. Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004;109:138-143
46. Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 2006;9:245-253
47. Farinati F, Rugge M, Di Mario F, et al. Early and advanced gastric cancer in the follow up of moderate and severe gastric dysplasia patients. A prospective study. I.G.G.E.D.-Interdisciplinary Group on Gastric Epithelial Dysplasia. Endoscopy 1993;25:261-264
48. Lauwers GY, Srivastava A. Gastric preneoplastic lesions and epithelial dysplasia. Gastroenterol Clin North Am 2007;36:813-829
49. Kyrlagkitsis I, Karamanolis DG. Premalignant lesions and conditions for gastric adenocarcinoma: diagnosis, management and surveillance guidelines. Hepatogastroenterology 2003;50:592-600.
50. Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia:randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881-1888
51. Mera R, Fontham ET, Bravo LE, et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005;54:1536-1540
52. You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006;98:974-983
53. Wu CY, Kuo KN, Wu MS, et al. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009;137:1641-1648, e1-2.
54. de Vries AC, Kuipers EJ, Rauws EA. Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn? Am J Gastroenterol 2009;104:1342-1345
55. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China:a randomized controlled trial. JAMA 2004;291:187-194
56. Watari J, Das KK, Amenta PS, et al. Effect of eradication of Helicobacter pylori on the histology and cellular phenotype of gastric intestinal metaplasia. Clin Gastroenterol Hepatol 2008;6:409-417
57. Lahner E, Bordi C, Cattaruzza MS, et al. Long-term follow-up in atrophic body gastritis patients:atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection. Aliment Pharmacol Ther 2005;22:471-481
58. Bravo JC, Correa P. Sulphomucins favour adhesion of Helicobacter pylori to metaplastic gastric mucosa. J Clin Pathol 1999;52:137-140
59. Kang HY, Kim N, Park YS, et al. Progression of atrophic gastritis and intestinal metaplasia drives Helicobacter pylori out of the gastric mucosa. Dig Dis Sci 2006;51:2310-2315
60. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-1825